Breckenridge Pharmaceutical, Inc: Drug Recall

Recall #D-0562-2024 · 05/17/2024

Class II: Risk

Recall Details

Recall Number: D-0562-2024
Classification: Class II
Product Type: Drug
Recalling Firm: Breckenridge Pharmaceutical, Inc
Status: Completed
Date Initiated: 05/17/2024
Location: Berlin, CT, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 165,678, 90-count bottles

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Product Description

Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90

Distribution Pattern

Nationwide in the USA

Other Recalls by Breckenridge Pharmaceutical, Inc

Class II: Risk 11/24/2025

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Class II: Risk 11/24/2025

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Class II: Risk 10/09/2025

CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
Class II: Risk 08/08/2025

CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
Class II: Risk 07/25/2025

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

View all recalls by Breckenridge Pharmaceutical, Inc →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.